Literature DB >> 1735829

Dose-dependent responses to macrophage-targeted glucocerebrosidase in a child with Gaucher disease.

N W Barton1, R O Brady, J M Dambrosia, S H Doppelt, S C Hill, C A Holder, H J Mankin, G J Murray, G C Zirzow, R I Parker.   

Abstract

Long-term studies of a child with Gaucher disease indicated that the response to treatment with macrophage-targeted glucocerebrosidase (glucosylceramidase) is dose dependent, and that the hematologic response precedes the skeletal response.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1735829     DOI： 10.1016/s0022-3476(05)80444-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  9 in total

Review 1.  Alglucerase. A pharmacoeconomic appraisal of its use in the treatment of Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Pharmacoeconomics       Date:  1995-01       Impact factor: 4.981

Review 2.  Lysosomal storage diseases: mechanisms of enzyme replacement therapy.

Authors:  G Bou-Gharios; D Abraham; I Olsen
Journal:  Histochem J       Date:  1993-09

3.  The impact of Gaucher disease and its treatment on quality of life.

Authors:  R P Hayes; K A Grinzaid; E B Duffey; L J Elsas
Journal:  Qual Life Res       Date:  1998-08       Impact factor: 4.147

Review 4.  Gaucher disease: Progress and ongoing challenges.

Authors:  Pramod K Mistry; Grisel Lopez; Raphael Schiffmann; Norman W Barton; Neal J Weinreb; Ellen Sidransky
Journal:  Mol Genet Metab       Date:  2016-11-17       Impact factor: 4.797

Review 5.  Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

Authors:  R O Brady; G J Murray; N W Barton
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

6.  Enzyme replacement therapy for murine mucopolysaccharidosis type VII.

Authors:  M S Sands; C Vogler; J W Kyle; J H Grubb; B Levy; N Galvin; W S Sly; E H Birkenmeier
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

Review 7.  Alglucerase. A review of its therapeutic use in Gaucher's disease.

Authors:  R Whittington; K L Goa
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

8.  Resolution of a proximal humeral defect in type-1 Gaucher disease by enzyme replacement therapy.

Authors:  G M Pastores; G Hermann; K Norton; R J Desnick
Journal:  Pediatr Radiol       Date:  1995

Review 9.  Imiglucerase in the treatment of Gaucher disease: a history and perspective.

Authors:  Patrick B Deegan; Timothy M Cox
Journal:  Drug Des Devel Ther       Date:  2012-04-18       Impact factor: 4.162
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.